Phathom Pharmaceuticals Key Executives
This section highlights Phathom Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Phathom Pharmaceuticals
(Showing 0 of )
Phathom Pharmaceuticals Earnings
This section highlights Phathom Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-06 | $-1.29 | $-0.79 |
| Read Transcript | Q3 | 2024 | 2024-11-10 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-08-10 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-1.43 | $-1.42 |
| Read Transcript | Q4 | 2023 | 2024-03-07 | $-0.92 | $-0.80 |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
$6.69
Stock Price
$465.87M
Market Cap
427
Employees
Florham Park, NJ
Location
Financial Statements
Access annual & quarterly financial statements for Phathom Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $55.25M | $682.00K | $- | $- | $- |
| Cost of Revenue | $7.97M | $167.00K | $620.00K | $521.00K | $300.00K |
| Gross Profit | $47.28M | $515.00K | $-620.00K | $-521.00K | $-300.00K |
| Gross Profit Ratio | 85.57% | 75.50% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $34.08M | $49.90M | $71.44M | $72.34M | $98.15M |
| General and Administrative Expenses | $- | $- | $101.00M | $62.74M | $27.52M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $290.66M | $117.93M | $101.00M | $62.74M | $27.52M |
| Other Expenses | $- | $- | $-110.00K | $-2.06M | $-8.00K |
| Operating Expenses | $324.75M | $167.83M | $172.44M | $135.08M | $125.67M |
| Cost and Expenses | $332.72M | $167.99M | $172.44M | $135.08M | $125.67M |
| Interest Income | $15.16M | $7.88M | $2.13M | $41.00K | $1.09M |
| Interest Expense | $72.01M | $41.97M | $27.30M | $6.79M | $4.58M |
| Depreciation and Amortization | $795.00K | $575.00K | $620.00K | $521.00K | $300.00K |
| EBITDA | $-261.52M | $-159.05M | $-171.82M | $-134.56M | $-124.19M |
| EBITDA Ratio | -473.33% | -23320.97% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-277.47M | $-167.31M | $-172.44M | $-135.08M | $-125.67M |
| Operating Income Ratio | -502.18% | -24532.55% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-56.86M | $-34.28M | $-25.28M | $-8.80M | $-3.40M |
| Income Before Tax | $-334.33M | $-201.59M | $-197.72M | $-143.88M | $-129.07M |
| Income Before Tax Ratio | -605.09% | -29558.94% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $25.28M | $4.21M | $4.25M |
| Net Income | $-334.33M | $-201.59M | $-223.01M | $-148.09M | $-133.32M |
| Net Income Ratio | -605.09% | -29558.94% | 0.00% | 0.00% | 0.00% |
| EPS | $-5.29 | $-3.93 | $-5.70 | $-4.00 | $-4.01 |
| EPS Diluted | $-5.29 | $-3.93 | $-5.70 | $-4.00 | $-4.01 |
| Weighted Average Shares Outstanding | 63.18M | 51.29M | 39.12M | 37.00M | 33.23M |
| Weighted Average Shares Outstanding Diluted | 63.18M | 51.29M | 39.12M | 37.00M | 33.23M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29.66M | $16.35M | $7.32M | $1.91M | $682.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $3.81M | $2.36M | $1.38M | $426.00K | $-223.00K | $121.00K | $123.00K | $146.00K | $168.00K | $175.00K | $149.00K | $128.00K | $135.00K | $130.00K | $131.00K | $125.00K | $- | $- | $- | $- |
| Gross Profit | $25.85M | $14.00M | $5.95M | $1.49M | $905.00K | $-121.00K | $-123.00K | $-146.00K | $-168.00K | $-175.00K | $-149.00K | $-128.00K | $-135.00K | $-130.00K | $-131.00K | $-125.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 87.14% | 85.60% | 81.20% | 77.70% | 132.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $8.58M | $8.69M | $7.38M | $9.43M | $13.39M | $12.26M | $12.76M | $11.48M | $15.95M | $19.02M | $18.82M | $17.66M | $13.55M | $16.61M | $21.60M | $20.58M | $41.65M | $25.77M | $14.86M | $15.87M |
| General and Administrative Expenses | $- | $- | $75.87M | $- | $60.93M | $23.40M | $18.94M | $18.60M | $30.70M | $23.51M | $26.55M | $20.25M | $19.49M | $16.53M | $13.72M | $13.00M | $10.79M | $7.06M | $5.16M | $4.51M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $-3.93M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $76.68M | $76.10M | $75.87M | $62.01M | $57.00M | $23.40M | $18.94M | $18.60M | $30.70M | $23.51M | $26.55M | $20.25M | $19.49M | $16.53M | $13.72M | $13.00M | $10.79M | $7.06M | $5.16M | $4.51M |
| Other Expenses | $- | $- | $-6.00K | $-43.00K | $-14.00K | $-197.00K | $3.00K | $20.00K | $-89.00K | $-11.00K | $-2.00K | $-7.00K | $-17.00K | $-2.05M | $10.00K | $-1.00K | $-2.00K | $-4.00K | $- | $-1.00K |
| Operating Expenses | $85.27M | $84.79M | $83.25M | $71.44M | $70.39M | $35.66M | $31.70M | $30.08M | $46.64M | $42.53M | $45.36M | $37.91M | $33.04M | $33.14M | $35.32M | $33.58M | $52.44M | $32.83M | $20.02M | $20.38M |
| Cost and Expenses | $89.08M | $87.15M | $84.62M | $71.87M | $70.56M | $35.66M | $31.70M | $30.08M | $46.64M | $42.53M | $45.36M | $37.91M | $33.04M | $33.14M | $35.32M | $33.58M | $52.44M | $32.83M | $20.02M | $20.38M |
| Interest Income | $3.51M | $3.71M | $3.62M | $4.31M | $3.35M | $2.72M | $348.00K | $1.46M | $1.29M | $726.00K | $112.00K | $7.00K | $6.00K | $8.00K | $13.00K | $14.00K | $16.00K | $15.00K | $182.00K | $878.00K |
| Interest Expense | $18.59M | $18.48M | $17.76M | $17.17M | $13.03M | $10.11M | $9.62M | $9.22M | $9.60M | $9.28M | $5.67M | $2.76M | $2.77M | $1.49M | $1.26M | $1.27M | $1.30M | $1.29M | $1.26M | $738.00K |
| Depreciation and Amortization | $193.00K | $191.00K | $197.00K | $214.00K | $185.00K | $121.00K | $123.00K | $146.00K | $168.00K | $175.00K | $149.00K | $128.00K | $135.00K | $130.00K | $131.00K | $125.00K | $106.00K | $88.00K | $77.00K | $52.00K |
| EBITDA | $-55.66M | $-66.90M | $-73.48M | $-65.47M | $-66.36M | $-33.02M | $-31.23M | $-28.45M | $-45.28M | $-41.64M | $-45.10M | $-37.78M | $-32.92M | $-35.05M | $-35.16M | $-33.45M | $-52.33M | $-32.73M | $-19.76M | $-19.35M |
| EBITDA Ratio | -187.65% | -409.14% | -1052.74% | -3647.49% | -9729.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-59.42M | $-70.80M | $-77.30M | $-69.95M | $-69.88M | $-35.66M | $-31.70M | $-30.08M | $-46.64M | $-42.53M | $-45.36M | $-37.91M | $-33.04M | $-33.14M | $-35.32M | $-33.58M | $-52.44M | $-32.83M | $-20.02M | $-20.38M |
| Operating Income Ratio | -200.30% | -432.95% | -1055.43% | -3658.68% | -10245.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $-15.03M | $-14.78M | $-14.15M | $-12.90M | $-9.70M | $-7.58M | $-9.26M | $-7.74M | $-8.40M | $-8.56M | $-5.56M | $-2.76M | $-2.79M | $-3.52M | $-1.23M | $-1.26M | $-1.28M | $-1.27M | $-1.08M | $234.00K |
| Income Before Tax | $-74.45M | $-85.58M | $-91.45M | $-82.85M | $-79.57M | $-43.24M | $-40.97M | $-37.81M | $-55.05M | $-51.09M | $-50.92M | $-40.66M | $-35.83M | $-36.66M | $-36.55M | $-34.84M | $-53.72M | $-34.10M | $-21.10M | $-20.14M |
| Income Before Tax Ratio | -250.98% | -523.34% | -1248.58% | -4333.26% | -11667.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $170.72K | $-16.74M | $7.27M | $9.62M | $-146.00K | $8.40M | $8.56M | $5.67M | $2.76M | $-6.79M | $-563.00K | $1.27M | $1.27M | $1.19M | $1.28M | $182.00K | $737.00K |
| Net Income | $-74.45M | $-85.58M | $-91.45M | $-82.85M | $-79.57M | $-43.24M | $-40.97M | $-37.67M | $-63.45M | $-59.65M | $-50.92M | $-43.42M | $-35.83M | $-36.66M | $-36.55M | $-34.84M | $-53.72M | $-34.10M | $-21.10M | $-20.14M |
| Net Income Ratio | -250.98% | -523.34% | -1248.58% | -4333.26% | -11667.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.05 | $-1.32 | $-1.56 | $-1.42 | $-1.39 | $-0.76 | $-0.84 | $-0.89 | $-1.54 | $-1.54 | $-1.33 | $-1.14 | $-0.95 | $-0.98 | $-1.00 | $-0.96 | $-1.58 | $-1.02 | $-0.64 | $-0.62 |
| EPS Diluted | $-1.05 | $-1.32 | $-1.56 | $-1.42 | $-1.39 | $-0.76 | $-0.84 | $-0.89 | $-1.54 | $-1.54 | $-1.33 | $-1.14 | $-0.95 | $-0.98 | $-1.00 | $-0.96 | $-1.58 | $-1.02 | $-0.64 | $-0.62 |
| Weighted Average Shares Outstanding | 71.04M | 64.63M | 58.56M | 58.37M | 57.29M | 56.78M | 48.50M | 42.35M | 41.31M | 38.82M | 38.27M | 38.04M | 37.76M | 37.30M | 36.64M | 36.30M | 34.06M | 33.37M | 33.00M | 32.47M |
| Weighted Average Shares Outstanding Diluted | 71.04M | 64.63M | 58.56M | 58.37M | 57.29M | 56.78M | 48.50M | 42.35M | 41.31M | 38.82M | 38.27M | 38.04M | 37.76M | 37.30M | 36.64M | 36.30M | 34.06M | 33.37M | 33.00M | 32.47M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $297.26M | $381.39M | $155.38M | $183.26M | $287.50M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $297.26M | $381.39M | $155.38M | $183.26M | $287.50M |
| Net Receivables | $38.80M | $1.64M | $- | $- | $82.00K |
| Inventory | $3.21M | $1.21M | $- | $- | $-82.00K |
| Other Current Assets | $20.87M | $13.19M | $10.25M | $6.53M | $7.74M |
| Total Current Assets | $360.13M | $397.43M | $160.51M | $186.53M | $291.37M |
| Property Plant Equipment Net | $2.09M | $3.62M | $3.49M | $2.56M | $3.36M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $505.00K | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $16.09M | $12.79M | $299.00K | $341.00K | $384.00K |
| Total Non-Current Assets | $18.18M | $16.41M | $4.30M | $2.90M | $3.74M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $378.32M | $413.84M | $164.81M | $189.43M | $295.11M |
| Account Payables | $10.51M | $12.60M | $10.00M | $5.15M | $16.78M |
| Short Term Debt | $1.00M | $726.00K | $1.42M | $974.00K | $8.30M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $74.22M | $25.45M | $14.82M | $12.80M | $30.44M |
| Total Current Liabilities | $85.73M | $38.78M | $26.24M | $18.92M | $55.52M |
| Long Term Debt | $- | $138.30M | $96.36M | $90.85M | $41.19M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $546.17M | $309.52M | $117.03M | $7.50M | $4.12M |
| Total Non-Current Liabilities | $546.17M | $447.82M | $213.39M | $98.35M | $45.32M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $631.90M | $486.60M | $239.62M | $117.28M | $100.84M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $6.00K | $5.00K | $3.00K | $3.00K | $3.00K |
| Retained Earnings | $-1.26B | $-928.68M | $-727.09M | $-529.37M | $-385.49M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $0 |
| Other Total Stockholders Equity | $1.01B | $855.92M | $652.28M | $601.52M | $579.75M |
| Total Stockholders Equity | $-253.58M | $-72.76M | $-74.81M | $72.16M | $194.27M |
| Total Equity | $-253.58M | $-72.76M | $-74.81M | $72.16M | $194.27M |
| Total Liabilities and Stockholders Equity | $378.32M | $413.84M | $164.81M | $189.43M | $295.11M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $378.32M | $413.84M | $164.81M | $189.43M | $295.11M |
| Total Investments | $- | $2.86M | $505.00K | $- | $- |
| Total Debt | $501.00K | $139.03M | $97.07M | $91.34M | $49.02M |
| Net Debt | $-296.76M | $-242.36M | $-58.31M | $-91.92M | $-238.48M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $297.26M | $334.68M | $276.24M | $322.23M | $381.39M | $213.68M | $248.85M | $129.57M | $155.38M | $196.84M | $207.39M | $138.09M | $183.26M | $224.62M | $209.67M | $237.97M | $287.50M | $226.36M | $247.27M | $256.67M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $297.26M | $334.68M | $276.24M | $322.23M | $381.39M | $213.68M | $248.85M | $129.57M | $155.38M | $196.84M | $207.39M | $138.09M | $183.26M | $224.62M | $209.67M | $237.97M | $287.50M | $226.36M | $247.27M | $256.67M |
| Net Receivables | $38.80M | $21.05M | $10.88M | $3.88M | $1.64M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $82.00K | $- | $- | $- |
| Inventory | $3.21M | $3.11M | $2.18M | $1.46M | $1.21M | $111.00K | $111.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-82.00K | $- | $- | $- |
| Other Current Assets | $20.87M | $14.98M | $15.50M | $12.75M | $13.19M | $12.94M | $8.76M | $10.27M | $10.25M | $1.95M | $3.73M | $15.30M | $6.53M | $1.39M | $3.34M | $9.67M | $7.74M | $1.60M | $2.82M | $5.16M |
| Total Current Assets | $360.13M | $373.82M | $304.79M | $340.31M | $397.43M | $226.73M | $257.72M | $139.84M | $160.51M | $196.84M | $209.26M | $145.74M | $186.53M | $225.31M | $211.34M | $242.81M | $291.37M | $227.16M | $248.68M | $261.83M |
| Property Plant Equipment Net | $2.09M | $2.49M | $2.86M | $3.23M | $3.62M | $3.66M | $3.04M | $3.36M | $3.49M | $3.31M | $3.44M | $2.50M | $2.56M | $2.72M | $2.95M | $3.17M | $3.36M | $3.35M | $3.36M | $1.71M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $2.86M | $2.87M | $2.86M | $2.86M | $528.00K | $505.00K | $505.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $16.09M | $10.73M | $8.86M | $10.09M | $9.93M | $3.75M | $3.75M | $299.00K | $299.00K | $1.78M | $805.00K | $805.00K | $341.00K | $341.00K | $291.00K | $385.00K | $384.00K | $381.00K | $381.00K | $381.00K |
| Total Non-Current Assets | $18.18M | $13.22M | $14.59M | $16.18M | $16.41M | $10.27M | $7.32M | $4.17M | $4.30M | $5.09M | $4.25M | $3.31M | $2.90M | $3.06M | $3.24M | $3.55M | $3.74M | $3.73M | $3.74M | $2.09M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $0 | $- | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $378.32M | $387.04M | $319.38M | $356.50M | $413.84M | $236.99M | $265.04M | $144.01M | $164.81M | $201.93M | $213.50M | $149.05M | $189.43M | $228.38M | $214.58M | $246.36M | $295.11M | $230.89M | $252.42M | $263.92M |
| Account Payables | $10.51M | $7.13M | $7.66M | $8.40M | $12.60M | $5.79M | $4.17M | $4.80M | $10.00M | $7.13M | $5.76M | $2.86M | $5.15M | $5.58M | $5.40M | $10.86M | $16.78M | $4.79M | $4.89M | $1.19M |
| Short Term Debt | $501.00K | $680.00K | $10.63M | $17.21M | $726.00K | $721.00K | $717.00K | $712.00K | $708.00K | $685.00K | $1.26M | $980.00K | $487.00K | $968.00K | $11.30M | $12.72M | $7.83M | $6.42M | $2.22M | $296.00K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $18.34M | $15.10M | $16.41M | $- | $- | $- | $-559.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $74.72M | $57.48M | $28.72M | $17.85M | $25.45M | $17.46M | $16.65M | $8.93M | $15.53M | $15.06M | $14.06M | $7.56M | $13.28M | $21.26M | $22.91M | $17.27M | $30.91M | $16.46M | $6.14M | $3.09M |
| Total Current Liabilities | $85.73M | $65.29M | $47.01M | $43.46M | $38.78M | $23.98M | $21.55M | $14.44M | $26.24M | $22.88M | $21.07M | $11.39M | $18.92M | $27.81M | $39.61M | $40.84M | $55.52M | $27.67M | $13.26M | $4.58M |
| Long Term Debt | $201.41M | $175.73M | $495.75M | $451.84M | $138.30M | $99.89M | $98.59M | $97.58M | $96.36M | $95.12M | $93.82M | $92.12M | $90.85M | $89.58M | $38.72M | $37.05M | $41.19M | $42.71M | $46.62M | $46.52M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $344.76M | $333.14M | $10.45M | $9.70M | $309.52M | $130.90M | $127.30M | $122.18M | $117.03M | $110.35M | $105.60M | $7.50M | $7.50M | $7.50M | $4.12M | $4.12M | $4.12M | $4.12M | $4.12M | $4.12M |
| Total Non-Current Liabilities | $546.17M | $508.87M | $506.20M | $461.54M | $447.82M | $230.79M | $225.89M | $219.76M | $213.39M | $205.47M | $199.43M | $99.62M | $98.35M | $97.08M | $42.84M | $41.18M | $45.32M | $46.83M | $50.74M | $50.64M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $631.90M | $574.16M | $553.21M | $505.00M | $486.60M | $254.76M | $247.44M | $234.21M | $239.62M | $228.35M | $220.50M | $111.01M | $117.28M | $124.90M | $82.45M | $82.02M | $100.84M | $74.50M | $64.00M | $55.22M |
| Preferred Stock | $- | $- | $- | $- | $0 | $- | $- | $1 | $- | $- | $- | $- | $- | $0 | $- | $0 | $- | $- | $- | $- |
| Common Stock | $6.00K | $6.00K | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K | $4.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $3.00K | $2.00K |
| Retained Earnings | $-1.26B | $-1.19B | $-1.10B | $-1.01B | $-928.68M | $-849.12M | $-805.87M | $-764.91M | $-727.09M | $-672.05M | $-620.96M | $-570.03M | $-529.37M | $-493.54M | $-456.88M | $-420.33M | $-385.49M | $-331.77M | $-297.66M | $-276.56M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $-0 | $- | $- | $0 | $- | $- | $- | $- | $- | $-0 | $0 | $-0 | $0 | $0 | $- | $- |
| Other Total Stockholders Equity | $1.01B | $1.00B | $869.15M | $863.03M | $855.92M | $831.34M | $823.47M | $674.71M | $652.28M | $645.62M | $613.95M | $608.07M | $601.52M | $597.02M | $589.01M | $584.67M | $579.75M | $488.15M | $486.08M | $485.25M |
| Total Stockholders Equity | $-253.58M | $-187.11M | $-233.83M | $-148.50M | $-72.76M | $-17.77M | $17.60M | $-90.19M | $-74.81M | $-26.42M | $-7.00M | $38.03M | $72.16M | $103.48M | $132.13M | $164.34M | $194.27M | $156.39M | $188.42M | $208.69M |
| Total Equity | $-253.58M | $-187.11M | $-233.83M | $-148.50M | $-72.76M | $-17.77M | $17.60M | $-90.19M | $-74.81M | $-26.42M | $-7.00M | $38.03M | $72.16M | $103.48M | $132.13M | $164.34M | $194.27M | $156.39M | $188.42M | $208.69M |
| Total Liabilities and Stockholders Equity | $378.32M | $387.04M | $319.38M | $356.50M | $413.84M | $236.99M | $265.04M | $144.01M | $164.81M | $201.93M | $213.50M | $149.05M | $189.43M | $228.38M | $214.58M | $246.36M | $295.11M | $230.89M | $252.42M | $263.92M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $378.32M | $387.04M | $319.38M | $356.50M | $413.84M | $236.99M | $265.04M | $144.01M | $164.81M | $201.93M | $213.50M | $149.05M | $189.43M | $228.38M | $214.58M | $246.36M | $295.11M | $230.89M | $252.42M | $263.92M |
| Total Investments | $- | $- | $2.86M | $2.87M | $2.86M | $2.86M | $528.00K | $505.00K | $505.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $201.91M | $176.41M | $506.38M | $469.05M | $139.03M | $100.61M | $99.31M | $98.30M | $97.07M | $95.81M | $94.45M | $92.61M | $91.34M | $90.07M | $49.54M | $49.30M | $49.02M | $48.69M | $48.42M | $46.67M |
| Net Debt | $-95.35M | $-158.27M | $230.14M | $146.82M | $-242.36M | $-113.07M | $-149.53M | $-31.28M | $-58.31M | $-101.03M | $-112.94M | $-45.48M | $-91.92M | $-134.55M | $-160.13M | $-188.68M | $-238.48M | $-177.67M | $-198.85M | $-210.00M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-334.33M | $-201.59M | $-197.72M | $-143.88M | $-129.07M |
| Depreciation and Amortization | $795.00K | $575.00K | $620.00K | $521.00K | $323.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-95.00K |
| Stock Based Compensation | $24.05M | $45.02M | $24.13M | $16.81M | $5.84M |
| Change in Working Capital | $- | $-13.64M | $5.44M | $-27.48M | $51.72M |
| Accounts Receivables | $-37.16M | $-1.64M | $- | $- | $- |
| Inventory | $836.00K | $-9.44M | $- | $- | $- |
| Accounts Payables | $34.94M | $6.41M | $8.68M | $-9.79M | $24.01M |
| Other Working Capital | $- | $-8.97M | $-3.24M | $-17.68M | $27.71M |
| Other Non Cash Items | $42.71M | $32.06M | $21.00M | $5.41M | $1.59M |
| Net Cash Provided by Operating Activities | $-266.77M | $-137.58M | $-146.53M | $-148.62M | $-69.69M |
| Investments in Property Plant and Equipment | $- | $-1.63M | $-1.04M | $-328.00K | $-1.04M |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-135.00K | $- | $-1.18M | $-330.00K | $-1.19M |
| Net Cash Used for Investing Activities | $-135.00K | $-1.63M | $-1.04M | $-328.00K | $-1.04M |
| Debt Repayment | $59.40M | $39.32M | $- | $42.76M | $25.00M |
| Common Stock Issued | $121.78M | $155.46M | $24.60M | $1.29M | $88.83M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.60M | $172.80M | $95.45M | $1.94M | $629.00K |
| Net Cash Used Provided by Financing Activities | $182.77M | $367.58M | $120.04M | $44.71M | $114.46M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-84.13M | $228.37M | $-27.53M | $-104.24M | $43.73M |
| Cash at End of Period | $300.12M | $384.26M | $155.89M | $183.26M | $287.50M |
| Cash at Beginning of Period | $384.26M | $155.89M | $183.42M | $287.50M | $243.76M |
| Operating Cash Flow | $-266.77M | $-137.58M | $-146.53M | $-148.62M | $-69.69M |
| Capital Expenditure | $- | $-1.63M | $-1.04M | $-328.00K | $-1.04M |
| Free Cash Flow | $-266.77M | $-139.21M | $-147.57M | $-148.94M | $-70.73M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-74.45M | $-85.58M | $-91.45M | $-82.85M | $-79.57M | $-43.24M | $-40.97M | $-37.81M | $-55.05M | $-51.09M | $-50.92M | $-40.66M | $-35.83M | $-36.66M | $-36.55M | $-34.84M | $-53.72M | $-34.10M | $-21.10M | $-20.14M |
| Depreciation and Amortization | $193.00K | $191.00K | $197.00K | $214.00K | $185.00K | $121.00K | $123.00K | $146.00K | $168.00K | $175.00K | $149.00K | $128.00K | $135.00K | $130.00K | $131.00K | $125.00K | $106.00K | $88.00K | $77.00K | $52.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-95.00K |
| Stock Based Compensation | $6.69M | $5.63M | $6.10M | $5.63M | $24.58M | $6.14M | $7.25M | $7.05M | $6.66M | $5.82M | $5.88M | $5.78M | $4.34M | $4.42M | $4.24M | $3.82M | $2.38M | $2.07M | $828.00K | $563.00K |
| Change in Working Capital | $-9.04M | $7.65M | $-626.00K | $-7.02M | $676.00K | $-2.41M | $4.43M | $-16.34M | $208.00K | $2.69M | $14.83M | $-12.30M | $-11.54M | $345.00K | $3.30M | $-19.59M | $22.50M | $10.70M | $10.51M | $8.01M |
| Accounts Receivables | $-17.75M | $-10.18M | $-7.00M | $-2.24M | $-1.64M | $111 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $-5.58M | $864.00K | $268.00K | $-416.00K | $-9.33M | $-111 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $19.94M | $11.32M | $8.69M | $-5.01M | $10.27M | $4.59M | $2.86M | $-11.30M | $3.92M | $1.90M | $8.94M | $-6.07M | $-162.00K | $3.23M | $-3.34M | $-9.52M | $5.50M | $10.38M | $6.64M | $1.49M |
| Other Working Capital | $-5.66M | $5.64M | $-2.59M | $653.00K | $1.38M | $-7.00M | $1.57M | $-5.04M | $-3.71M | $796.00K | $-315.00K | $-6.22M | $-11.38M | $-2.89M | $6.65M | $-10.07M | $17.00M | $325.00K | $3.87M | $6.51M |
| Other Non Cash Items | $13.15M | $8.53M | $19.59M | $28.74M | $10.33M | $7.48M | $6.96M | $7.29M | $7.32M | $7.39M | $4.34M | $1.96M | $1.47M | $2.70M | $517.00K | $721.00K | $533.00K | $518.00K | $345.00K | $199.00K |
| Net Cash Provided by Operating Activities | $-63.46M | $-63.57M | $-70.72M | $-69.02M | $-43.80M | $-31.91M | $-22.20M | $-39.67M | $-40.70M | $-35.02M | $-25.72M | $-45.10M | $-41.42M | $-29.07M | $-28.36M | $-49.77M | $-28.20M | $-20.73M | $-9.34M | $-11.42M |
| Investments in Property Plant and Equipment | $-5.00K | $86.00K | $-46.00K | $-40.00K | $-475.00K | $-939.00K | $-6.00K | $-214.00K | $-412.00K | $-134.00K | $-428.00K | $-67.00K | $-100.00K | $-14.00K | $-45.00K | $-169.00K | $-124.00K | $-183.00K | $-57.00K | $-676.00K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $-130.00K | $- | $-47.00K | $-1.65M | $- | $- | $- | $-1.18M | $- | $- | $-187.00K | $-330.00K | $- | $- | $-190.00K | $-1.19M | $- | $- | $-696.00K |
| Net Cash Used for Investing Activities | $-5.00K | $-44.00K | $-46.00K | $-40.00K | $-475.00K | $-939.00K | $-6.00K | $-214.00K | $-412.00K | $-134.00K | $-428.00K | $-67.00K | $-100.00K | $-14.00K | $-45.00K | $-169.00K | $-124.00K | $-183.00K | $-57.00K | $-676.00K |
| Debt Repayment | $24.75M | $- | $24.75M | $9.90M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $42.76M | $- | $- | $- | $- | $- | $25.00M |
| Common Stock Issued | $- | $121.78M | $21.00K | $- | $-141.40M | $13.00K | $141.39M | $14.07M | $24.60M | $24.60M | $- | $- | $1.94M | $1.26M | $104.00K | $412.00K | $89.46M | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.30M | $282.00K | $21.00K | $- | $211.99M | $13.00K | $111.00K | $- | $-24.60M | $- | $95.45M | $- | $163.00K | $1.26M | $104.00K | $412.00K | $629.00K | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $26.05M | $122.06M | $24.77M | $9.90M | $211.99M | $13.00K | $141.50M | $14.07M | $- | $24.60M | $95.45M | $- | $163.00K | $44.03M | $104.00K | $412.00K | $89.46M | $- | $- | $25.00M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-37.41M | $61.30M | $-45.99M | $-59.16M | $167.72M | $-32.84M | $119.30M | $-25.81M | $-40.95M | $-10.55M | $69.30M | $-45.17M | $-41.36M | $14.95M | $-28.30M | $-49.52M | $61.13M | $-20.91M | $-9.40M | $12.91M |
| Cash at End of Period | $300.12M | $337.54M | $276.24M | $322.23M | $384.26M | $216.53M | $249.38M | $130.08M | $155.89M | $196.84M | $207.90M | $138.09M | $183.26M | $224.62M | $209.67M | $237.97M | $287.50M | $226.36M | $247.27M | $256.67M |
| Cash at Beginning of Period | $337.54M | $276.24M | $322.23M | $381.39M | $216.53M | $249.38M | $130.08M | $155.89M | $196.84M | $207.39M | $138.59M | $183.26M | $224.62M | $209.67M | $237.97M | $287.50M | $226.36M | $247.27M | $256.67M | $243.76M |
| Operating Cash Flow | $-63.46M | $-63.57M | $-70.72M | $-69.02M | $-43.80M | $-31.91M | $-22.20M | $-39.67M | $-40.70M | $-35.02M | $-25.72M | $-45.10M | $-41.42M | $-29.07M | $-28.36M | $-49.77M | $-28.20M | $-20.73M | $-9.34M | $-11.42M |
| Capital Expenditure | $-5.00K | $86.00K | $-46.00K | $-40.00K | $-475.00K | $-939.00K | $-6.00K | $-214.00K | $-412.00K | $-134.00K | $-428.00K | $-67.00K | $-100.00K | $-14.00K | $-45.00K | $-169.00K | $-124.00K | $-183.00K | $-57.00K | $-676.00K |
| Free Cash Flow | $-63.46M | $-63.49M | $-70.77M | $-69.06M | $-44.27M | $-32.85M | $-22.21M | $-39.88M | $-41.11M | $-35.15M | $-26.14M | $-45.17M | $-41.52M | $-29.08M | $-28.41M | $-49.93M | $-28.32M | $-20.91M | $-9.40M | $-12.09M |
Phathom Pharmaceuticals Dividends
Explore Phathom Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Phathom Pharmaceuticals News
Read the latest news about Phathom Pharmaceuticals, including recent articles, headlines, and updates.
Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham Annabel Samimy - Stifel Kristen Kluska - Cantor Fitzgerald Paul Choi - Goldman Sachs Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Results Call.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent business updates.
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update.
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET.
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets
FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today it has submitted a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA). The petition formally requests correction of the Orange Book listings for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets to accurately reflect the full 10-year NCE exclusivity period until May 3, 2032.
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround
Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Paul Choi - Goldman Sachs Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December:
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update.
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting
FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, being held October 25-30 in Philadelphia, PA. VOQUEZNA is approved for the relief of heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (Non-Erosive GERD), for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn, and in combination with antibiotics for the eradication of Helicobacter pylori (H. pylori) infection.1 VOQUEZNA is the first and only U.S. Food and Drug Administration (FDA)-approved potassium-competitive acid blocker (PCAB).2
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT)
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty.
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants
FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares of its common stock and pre-funded warrants to purchase 2,608,922 shares of common stock. The shares of common stock are being sold at a price of $11.50 per share and the pre-funded warrants are being sold at a price of $11.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Phathom from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $130 million. The offering is expected to close on or about August 20, 2024, subject to satisfaction of customary closing conditions.
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President and CEO Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Azmi Nabulsi - Chief Operating Officer Conference Call Participants Annabel Samimy - Stifel Joseph Stringer - Needham & Company Yatin Suneja - Guggenheim Paul Choi - Goldman Sachs Chase Knickerbocker - Craig-Hallum Matthew Caufield - H.C. Wainwright Operator Hello, and welcome to Phathom Pharmaceuticals Second Quarter 2024 Earnings Results Call.
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the second quarter of 2024, and provided recent business updates.
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA represents the first major innovation in GERD treatment in over 30 years and the only FDA-approved treatment of its kind available in the U.S. A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J.
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation.
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company's proportion of shorted stock is publicly available, it's pretty easy to see which companies are expected to lose value.
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q1 2024 Results Conference Call May 9, 2024 8:30 AM ET Company Participants Eric Sciorilli - Head of Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial & Business Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham & Company Paul Choi - Goldman Sachs Annabel Samimy - Stifel Matthew Caufield - H.C. Wainright Operator Hello, and welcome to Phathom Pharmaceuticals First Quarter 2024 Earnings Results Call.
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024, and provided recent business highlights.
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 9:30 a.m. ET.
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB) National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB)
Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
The FDA has set a target action date of July 19, 2024, for expanded approval of Voquenza, which would target the larger Non-Erosive GERD patient population. The global market for GERD therapies is expected to be $3.4 billion by 2032. A soon-to-be-initiated phase 3 study in 2024 is going to explore the use of Voquenza with "As Needed" dosing to treat Non-Erosive GERD patients.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for PHAT.